SAB Biotherapeutics (NASDAQ:SABSW – Get Free Report) is projected to release its results before the market opens on Tuesday, November 17th. Analysts expect the company to announce earnings of ($0.2746) per share and revenue of $0.12 million for the quarter.
SAB Biotherapeutics Stock Performance
NASDAQ:SABSW opened at $0.00 on Tuesday. The firm’s fifty day simple moving average is $0.01 and its 200 day simple moving average is $0.02. SAB Biotherapeutics has a twelve month low of $0.00 and a twelve month high of $0.20.
SAB Biotherapeutics Company Profile
SAB Biotherapeutics is a clinical-stage biotechnology company developing antibody-based medicines. Its proprietary platform uses genetically engineered cattle to produce fully human polyclonal antibodies, which the company researches for potential use against autoimmune diseases and infectious illnesses.
The company’s pipeline has included SAB-142, an investigational therapy being developed for type 1 diabetes, and SAB-185, an antibody treatment studied for infectious diseases. These are developmental programs, not established marketed products.
Founded in 2014 and based in Sioux Falls, South Dakota, SAB Biotherapeutics became a publicly traded company through a merger with Big Cypress Acquisition Corp.
Read More
- Five stocks we like better than SAB Biotherapeutics
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
